CardioFocus has announced that its HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation will be discussed at the 3rd Annual Frankfurt Atrial Fibrillation Academy Symposium (FAFA, Frankfurt, Germany, 9 March).
The FAFA Symposium, chaired by KR Julian Chun and Boris Schmidt, Cardioangiologisches Centrum Bethanien, Frankfurt, Germany, will highlight the latest innovations and research in atrial fibrillation therapy. The meeting will feature data presentations and live case broadcasts from cardiologists throughout Germany, as well as clinical discussion on topics such as the use of catheter ablation as a first-line therapy, preventing atrial fibrillation recurrence after ablation and the role of interventional procedures in atrial fibrillation treatment.
“In Germany alone there are over one million people suffering with atrial fibrillatiom. As that population grows, it is important to continually evaluate available techniques and technologies and their clinical impact. The focus of the FAFA meeting is on fostering discussion around the current treatment challenges as well as new advances, such as the HeartLight system, that may enable physicians to improve therapy outcomes,” said Chun.
“Atrial fibrillation has historically been very difficult to effectively treat, whether through drug therapy or advanced ablation techniques. We look forward to collaborating with our peers to further hone our understanding of this challenging condition,” said Schmidt.
HeartLight is the first catheter ablation system to incorporate an endoscope, laser energy source and compliant balloon catheter to enable direct visualisation of the beating heart while creating a more efficient, durable and precise cardiac ablation. It is CE-marked and clinically available in Europe and Australia, and currently the focus of a pivotal trial in the USA, expected to complete enrolment this year. The company announced that the team at Cardioangiologisches Centrum Bethanien in Frankfurt has performed over 180 cardiac ablation cases with the technology to date.